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S u m m a r y
Introduction. Defensins are peptide with antimicrobial, antiviral, antifungal activities 
and many other functions, such as induction of immunological response and antitumor 
activity. Changes in expression level of defensins was studied in many skin pathologies, 
including dermatological lesions such as psoriasis, atopic dermatitis and non-melanoma 
skin cancers (squamous cell carcinoma – SCC and basal cell carcinoma – BCC).
Aim. The objective of this study was to evaluate the mRNA profile of defensin-related 
genes’ transcripts as an additional molecular marker of non-melonoma skin pathologies: 
SCC, BCC and keratoacanthoma (KA).
Material and methods. Tissue samples were obtained from the central part of tumours (KA, 
SCC and BCC) and healthy margins. mRNA profile of genes coding defensins and proteins 
involved in their activation was determined using oligonucleotide microarrays (Affymetrix). Vali-
dation of the microarray analysis was performed using real-time QRT-PCR.
Results. Microarray analysis revealed changes in defensin-related genes’ profile. In all 
tumours DEFB4A (defensin beta 2) mRNA was up-regulated, compared with the healthy 
skin margins. Real-time QRT-PCR analysis showed increased DEFB4A transcript level both 
in KA and SCC comparing to BCC.
Conclusions. Defensin beta 2 mRNA level is a useful tool for the differentiation of KA 
and SCC from BCC. KA and SCC cannot be differentiated on the basis of the DEFB4A 
mRNA level.
S t r e s z c z e n i e
Wstęp. Defensyny stanowią grupę peptydów o aktywności antybakteryjnej, antywirusowej 
i antygrzybiczej. Uczestniczą także w indukcji odpowiedzi immunologicznej i przeciwnowo-
tworowej. Zmiany w poziomie ekspresji defensyn były badane w wielu patologiach skórnych, 
m.in. w łuszczycy, atopowym zapaleniu skóry, a także w niemelanotycznych nowotworach 
skóry (raku kolczystokomórkowym – SCC i raku podstawnokomórkowym – BCC).
Cel pracy. Celem tej pracy była ocena profilu mRNA genów kodujących defensyny 
oraz białka zaangażowane w indukcję ich ekspresji jako dodatkowego markera niemela-
notycznych patologii skórnych: SCC, BCC i rogowiaka kolczystokomórkowego (KA).
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INTRODUCTION
Defensins play a role as peptide antibiotics and con-
stitute an important element of anti-infectious protec-
tion (1). Apart from a direct antimicrobial action, defen-
sins also have many other functions, such as antifungal 
and antiviral activities, and chemotactic activity towards 
dendritic cells, T cells, basal cells and neutrophils. They 
may induce the production of certain chemokines and 
proinflammatory mediators; regulate complement activ-
ity; inhibit fibrinolysis and the production of certain gluco-
corticosteroids; intensify the proliferation of lymphocytes, 
endothelial cells and fibroblasts; bind and neutralize en-
dotoxins; stimulate healing of sores; induce degranula-
tion of basal cells and show antitumor activity (2). There 
are three groups of defensins – defensin α and β, and θ 
defensins – generated during the cyclisation of the two 
α defensins (1). In humans, six α (HNP 1-6 – human 
neutrophil peptide) and four β defensins (HBD 1-4) have 
been identified (3). Changed expression level of defen-
sins was reported in many pathologies, including der-
matological lesions such as psoriasis, acne vulgaris and 
atopic dermatitis (3-5). Examinations of cancer samples 
such as oesophageal squamous cell carcinoma, primary 
cutaneous squamous cell carcinoma (SCC) and basal 
cell carcinoma (BCC) also showed changes in defensins 
profile, suggesting their potential participation in these 
pathologies (6-8).
Knowledge of molecular markers of tumour transfor-
mation is essential for malignant diseases because it 
enables a diagnosis to be made of a disease already 
at the level of molecular changes, and it aids cause-
directed and efficient therapy. Non-melanoma skin 
cancers are still problematic in diagnosis because 
of clinical features resembling other pathologies i.e. 
 keratoacanthoma. Keratoacanthoma (KA) is a relative-
ly low-grade malignancy that histologically and clini-
cally resembles well-differentiated SCC (9, 10). It devel-
ops on unchanged skin in the form of a dome shaped, 
well-limited, hard nodule, usually with the same colour 
as the surrounding skin. The central part of the tumour 
has a crater-like depression with embanked margins, 
filled up with a keratin mass (11, 12). KA is charac-
terised by sometimes fast growth and a tendency to 
regression with scarring (11). BCC is the most com-
mon type of epithelial cancer; it is characterised by low 
clinical and histological malignancy and slow growth 
and rarely metastasises (13, 14). It is usually found on 
unchanged skin of the face and head and spreads in 
multiple directions with edgings. The multiple and mul-
tifocal presence of BCC is classified as nevoid BCC 
syndrome (Gorlin-Goltz syndrome) (13, 14). Clinically, 
the changes can be highly differentiated, superficial, 
corneous, nevus-like, scleroderma-like, nodular or 
sore-like (15). SCC is the second most frequent (after 
BCC) skin cancer. It originates from squamous epi-
thelium and develops from premalignant states (leu-
coplakia). It is characterised by fast growth and me-
tastases to regional lymph nodes. Clinical forms of 
SCC (sore and papular) morphologically resemble KA 
and BCC (9, 16). Therefore additional markers could 
facilitate diagnosis of non-melanoma skin pathologies.
Significant risk factors for BCC, SCC and KA are: UV 
radiation, ionized radiation, post-infectious and post-
drug immunosuppression, chemical carcinogens (ar-
senic, wood tars), old age, male gender, light skin type 
and human papilloma virus infection (8, 9, 16-20). Most 
of these factors influence immunological response. Due 
to its multidirectional activity, defensins may be involved 
not only in the molecular pathogenesis of non-melano-
ma skin cancers, but also in the immunological reaction 
leading to self-regression of KA. Understanding of the 
molecular mechanisms underlying KA regression may 
contribute to the development of an efficient treatment 
for skin cancers. Better knowledge about defensins 
level in non-melanoma skin pathologies could improve 
their diagnosis and could affect better understanding of 
molecular mechanism underlying these pathologies. Till 
this time there is no research comparing defensins pro-
file in these three non-melanoma pathologies (KA, SCC 
and BCC) in one study.
AIM
The aim of this work was to evaluate the mRNA pro-
file of defensin family transcripts as an additional mo-
lecular marker of nonmelonoma skin pathologies.
MATERIAL AND METHODS
The study included a group of 39 patient (16 fe-
males and 23 males; mean age 71.8 ± 9.5 years) 
diagnosed and treated in the Dermatology Clinics 
and Department of Medical University of Silesia in 
Katowice. Based on clinical and pathomorphological 
Materiał i metody. Wycinki uzyskano z centralnej części guza (KA, SCC i BCC) i margi-
nesów tkanki zdrowej. Profil mRNA genów kodujących defensyny oraz białka zaangażowane 
w indukcję ich ekspresji został wyznaczony techniką mikromacierzy oligonukleotydowych (Affy-
metrix). Walidację wyników przeprowadzono techniką QRT-PCR w czasie rzeczywistym.
Wyniki. Analiza techniką mikromacierzy wykazała zmiany profilu mRNA genów po-
wiązanych z defensynami. We wszystkich guzach stwierdzono nadekspresję mRNA de-
fensyny 2 (ang. defensin beta 2 – DEFB4A), w porównaniu do kontroli. Analiza techniką 
QRT-PCR w czasie rzeczywistym wykazała wzrost liczby kopii mRNA DEFB4A zarówno 
w KA, jak i SCC w porównaniu do BCC.
Wnioski. Poziom mRNA defensyny 2 jest przydatnym narzędziem w różnicowaniu KA 
i SCC od BCC. Rogowiak kolczystokomórkowy i rak kolczystokomórkowy nie mogą być 
różnicowane na podstawie liczby kopii mRNA DEFB4A.
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examination, 9 cases were kerathoacanthoma (KA), 
11 were squamous cell carcinoma (SCC) and 19 
were basal cell carcinoma (BCC). The changes 
were located on the skin of the face and head. The 
biopsies for the pathomorphological and molecular 
examination were obtained from the centre of the 
tumour and the margins of healthy tissues where 
no tumour cells were found. After surgical remov-
al, the samples were immediately preserved in the 
RNA stabilisation reagent RNAlater (Qiagen GmbH, 
Hilden, Germany). For microarray analysis 19 sam-
ples (6 KA, 3 SCC, 7 BCC and 4 margins of healthy 
tissues) were selected. The study was approved by 
the Bioethical Commission of the Medical University 
of Silesia. All of the patients were informed about the 
research and signed an informed consent form.
RNA extraction
Total RNA was extracted from the tissue samples 
using TRIZOL® reagent (Invitrogen Life Technolo-
gies, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. Total RNA extracts were treated 
with DNase I (MBI Fermentas, Vilnius, Lithuania) 
and purified with a RNeasy Mini Kit (Qiagen GmbH, 
Hilden, Germany) according to the manufacturer’s 
protocol. The quality of RNA was estimated by elec-
trophoresis on 1% agarose gel stained with ethid-
ium bromide. The RNA concentration was deter-
mined on the basis of absorbance values at 260 nm 
using a Gene Quant Pro spectrophotometer (LKB 
Biochrom Ltd., Cambridge, UK).
Microarray analysis
The analysis of the expression profile of defen-
sin-related genes was performed using commer-
cially available oligonucleotide microarrays HG-
U133A (Affymetrix, Santa Clara, CA) according to 
the manufacturer’s protocol. For finding significant 
genes comparative analysis was performed with 
the use of GeneSpring 12.6.1 platform (Agilent 
Technologies, Inc., Santa Clara, CA, USA) and PL-
Grid Infrastructure. The differences were analysed 
using the Oneway ANOVA test with Benjamini-Ho-
chberg Multiple Testing Correction and TukeyHSD 
Post Hoc test. Genes were considered as potential-
ly differentiating when FC ≥ 1.1 (fold change) and 
the significance level was set at p < 0.05.
Real-time QRT-PCR
The levels of the DEFB4A and β-actin transcripts 
were evaluated with the use of the real-time QRT-PCR 
TaqMan technique. The quantitative analysis was 
carried out using a Sequence Detector ABI PRISM™ 
7000 (Applied Biosystems, Foster, CA, USA). Ampli-
fication was performed with the use of commercially 
available oligonucleotide primers specific for DEFB4A 
and β-actin genes (DEFB4A: TaqMan Gene Expres-
sion Assay defensin, beta 4; β-actin: TaqMan B-actin 
Detection Reagents Kit, Applied Biosystems, Inc., 
Foster, CA, USA) and QuantiTect Probe RT-PCR 
Kit (Qiagen GmbH, Hilden, Germany). For the assay, 
positive (β-actin mRNA) and negative (no template) 
controls were used. The thermal profile for one-step 
RT-PCR was as follows: 50°C for 30 min for reverse 
transcription, 95°C for 15 min, 45 cycles at 94°C for 
15 s and at 60°C for 60 s. The standard curve was 
created for β-actin cDNA (TaqMan DNA Template 
Reagents Kit, Applied Biosystems, Inc., Foster, CA, 
USA). A standard curve was then generated by plot-
ting the Ct values against the log of the known amount 
of the β-actin cDNA copy number. The mRNA copy 
numbers of the gene examined were recalculated per 
1 µg of the total RNA. The RT-PCR products and the 
molecular weight marker pBR 322/Hae III (Fermentas 
International Inc., Ontario, Canada) were separated on 
8% polyacrylamide gel and visualised with silver salts. 
The length of the amplified fragments was assessed 
by analysis with GelScan v.1.45 software (Kucharc-
zyk TE, Warsaw, Poland). The statistical analysis of 
the real-time QRT-PCR results was performed with 
the use of Statistica version 9.0 software (StatSoft Inc., 
Oklahoma, USA). The one-way ANOVA followed by 
Tukey posthoc analysis of the logarithmic parameters 
were used to assess differences in the expression of 
the studied genes between KA, SCC and BCC. The 
differences between the tumour and the margin of 
the normal tissue were analysed using the t-test. All of 
results were expressed as means ± SD. The signifi-
cance level was set at p < 0.05.
RESULTS
Microarray analysis
In the present study, changes in transcriptome of de-
fensin family genes and genes coding proteins involved 
in their activation in non-melanoma skin pathologies were 
evaluated. Among 251 ID mRNA of defensin-related genes 
found in Affymetrix database (http://www.affymetrix.com) 
11 transcripts were differentiating in non-melanoma skin 
pathologies (Oneway ANOVA test with Benjamini-Hoch-
berg Multiple Testing Correction) (tab. 1A). Comparing to 
controls (C) 5 transcripts were differentiating for keratoac-
anthoma (KA), 4 for squamous cell carcinoma (SCC) and 
2 for basal cell carcinoma (BCC) (TukeyHSD Post Hoc 
test) (tab. 1B).
Among 11 transcripts 6 were differentiating in com-
parison to controls (fig. 1). Some of them were char-
acteristic only for particular group of transcriptomes, 
some were common for few groups. DUSP7 was char-
acteristic only for KA and TRAF3 was characteristic only 
for SCC. S100A8 and S100A9 were common for KA 
and SCC. MAPKAPK2 was common for KA and BCC. 
DEFB4A was common for all transcriptomes, compar-
ing to controls (KA, SCC, BCC).
Keratoacanthoma transcriptomes comparing to 
BCC showed 3 upregulated genes (S100A9, DUSP6, 
DUSP7) and one gene down-regulated (PELI2). Com-
paring to SCC also DUSP6 and DUSP7 were up-
regulated, while TRAF3 was down-regulated in KA. 
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In  comparison of SCC to BCC TRAF3 and MAPK3 were 
upregulated, LGR4 was down-regulated in SCC (fig. 2).
The most differentiating gene was DEFB4A which 
expression was upregulated in all skin non-melanoma 
pathologies comparing to controls. The highest fold 
change was for SCC (FC = 13.35), for KA FC = 9.86 
and for BCC FC = 7.86.
Real-time QRT-PCR
In the next step the transcript level of the DEFB4A 
gene was validated using the QRT-PCR assay. The 
DEFB4A mRNA level was higher in non-melanoma 
skin tumours than in the margins of the healthy tissue 
(tab. 2). Analysis of the DEFB4A transcript level in the 
tumours revealed significant difference between BCC, 
KA and SCC. The DEFB4A mRNA level in BCC was 
lower than in the KA and SCC groups (p = 0.0018, p = 
0.0014, respectively; Tukey’s test). No statistically sig-
nificant difference was found between KA and SCC (p 
= 0.9902) in the mRNA level of the DEFB4A gene. The 
DEFB4A transcript level in the margins of the healthy 
tissue was comparable (p = 0.3101).
Table 2. DEFB4A mRNA level in KA, SCC, BCC, C.
KA SCC BCC pa
Tumour 5.32 ± 0.74 5.21 ± 0.55 4.39 ± 0.59 0.0002
Margin 4.03 ± 1.22 4.42 ± 0.96 3.83 ± 1.11 NS
pb 0.0051 0.0123 0.0315
KA – keratoacanthoma; SCC – squamous cell carcinoma; BCC – basal cell 
carcinoma; C – controls (healthy skin margins); mean ± standard deviation; 
NS – not significant
aANOVA
bt test
Additionally, the expression of the β-actin gene 
was assessed as an endogenous control. The 
transcript level of this gene was similar in tumours 
and healthy tissues. Statistical analysis revealed 
a marked difference in the β-actin mRNA level in the 
tumours. However, the number of mRNA copies in 
the BCC group was lower than that in the KA group 
(p = 0.0012; Tukey’s test). In common with that 
found for the DEFB4A gene, the β-actin mRNA level 
in the margins of the healthy tissues was compa-
rable (p = 0.7467).
Table 1. The results of statistical analysis of 251 ID mRNA defensin-related genes in non-melanoma skin pathologies. A – The re-
sults of Oneway ANOVA test with Benjamini-Hochberg Multiple Testing Correction showing 11 differentiating entities at p < 0.05. 
B – TukeyHSD Post Hoc test results. Entities found to be differentially expressed between particular groups of samples are repre-
sented by grey colour.
A
P-value P all p < 0.05 p < 0.02 p < 0.01 p < 0.005 p < 0.001
Number of ID mRNA 251 11 2 2 2 1
B
Transcriptomes KA SCC BCC C
KA 11 3 5 5
SCC 8 11 3 4
BCC 6 8 11 2
C 6 7 9 11
KA – keratoacanthoma; SCC – squamous cell carcinoma; BCC – basal cell carcinoma; C – controls (healthy skin margins)
Fig. 1. Venn diagram showing number of transcripts differentiating 
in comparison to controls common for groups of transcriptomes: KA 
– keratoacanthoma, SCC – squamous cell carcinoma, BCC – basal 
cell carcinoma, C – controls (healthy skin margins).
Fig. 2. Heat-map for differentiating ID mRNA of defensin-related genes in transcriptomes of KA – keratoacanthoma, SCC – squamous cell 
carcinoma, BCC – basal cell carcinoma, C – controls (healthy skin margins).
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DISCUSSION
Defensins through multidirectional activity may influ-
ence many biological processes, including regulation 
of inflammatory response and wound healing (2). Many 
risk factors of NMSC (non-melanoma skin cancers) and 
KA can influence immunological reaction, thus poten-
tial involvement of defensins in mechanism underlying 
these pathologies cannot be excluded. Moreover, self-
-regression of KA is, inter alia, caused by changes in 
immunological reaction together with defensins’ activ-
ity (21). There is much controversy whether KA should 
be described as a mild or intermediate form of SCC or 
whether it should be considered as a totally separate 
benign malignancy (12, 13). KA needs to be differenti-
ated from both SCC and BCC. Some studies have been 
carried out to differentiate KA and SCC, other have com-
pared molecular changes in SCC and BCC (16, 22-25). 
Comparing all three pathologies together could show 
changes helpful in differentiating KA from BCC and SCC, 
as well as SCC from BCC. Moreover, such approach 
could reveal molecular markers which could have im-
pact on self-regression of KA. Therefore the aim of this 
study was to evaluate changes in mRNA profile of defen-
sin family genes and genes coding proteins involved in 
their activation in three non-melanoma pathologies: KA, 
SCC and BCC in one study.
mRNA profiles of KA, BCC and SCC transcriptomes 
were appointed with the use of oligonucleotide micro-
arrays (HGU133A, Affymetrix). Statistical analysis of 
transcriptomes assumed 251 ID mRNA of genes cod-
ing defensins and proteins involved in their activation, 
based on Affymetrix database results. Eleven ID mRNA 
were differentiating comparing to control samples. 
The only characteristic gene for KA was DUSP7, which 
expression was the highest in KA and it differentiated 
this lesion from controls, BCC and SCC. Additionally 
DUSP6 was also upregulated in KA, but only in com-
parison to SCC and BCC. DUSP7 and DUSP6 en-
code phosphatases which inactivate the MAP kinases 
ERK1/2 (26, 27). ERK1/2 are responsible for prolifera-
tion of skin SCC and inhibition of this pathway is crucial 
in anti-tumour therapy (28). Our research showed up-
regulated MAPK3 (ERK1) in SCC, comparing to BCC. 
Together with down-regulation of DUSP inactivators 
this result shows crucial role of ERK pathway in SCC. 
Moreover, the characteristic gene for SCC was TRAF3, 
which was upregulated in SCC comparing to controls, 
BCC and KA. TRAF3 is positive regulator of PI3K/AKT 
and JAK/STAT signalization and controls the growth 
of B and T cells (29). Both in KA and SCC, S100A8 
and S100A9 were upregulated comparing to controls. 
S100A9 was also upregulated in KA in comparison to 
BCC. S100A8 and S100A9 are calcium-binding pro-
teins, highly expressed at sites of acute and chronic 
inflammation including psoriatic epidermis (30). These 
two proteins forms calprotectin, a heteridimeric com-
plex which activate NF-kB signalization. Their high level 
was reported in inflammation, carcinogenesis and also 
during wound healing (30). Upregulated genes in BCC 
were PELI2 (comparing to KA) and LGR4 (comparing 
to SCC). PELI2 takes a part in TAK1 dependent activa-
tion of NF-kB, as well as in ERK phosphorylation (31). 
LGR4, G-protein-coupled receptor is crucial in the reg-
ulation of Wnt signalling (32). Common upregulated 
marker for KA and BCC was MAPKAPK2 (MK2). This 
gene is coding serine/threonine kinase phosphorylat-
ed by p38 mitogen-activated protein kinase and plays 
a crucial role in inflammatory response (33). The par-
ticipation of MK2 in immunological reaction along with 
protection of cells with DNA damage from apoptosis 
means that this kinase is crucial in skin tumours’ de-
velopment (33).
In all skin non-melanoma pathologies upregulated 
gene was DEFB4A (the official symbol of defensin 
beta 2 – HBD2, according to HUGO Gene Nomen-
clature Committee). DEFB4A belongs to the defensin 
family of small cationic peptides. It is produced by 
keratinocytes during inflammatory reactions, and it 
is present in lamellar bodies of the stimulated kerati-
nocytes in the granular epidermal layer, in the extra-
cellular matrix and in the stratum corneum (34, 35). 
DEFB4A is a protein closely associated with the devel-
opment and maintenance of inflammation in the skin. 
It activates many mechanisms of adaptive and innate 
immune responses, which eventually lead to develop-
ment of a local inflammatory response. Earlier research 
evaluated defensin beta 2 in relation to numerous pa-
thologies: psoriasis and atopic dermatitis, irritable bow-
el syndrome, lung cancer, bacterial infections, BCC 
and SCC (3, 6, 8, 36-40). In our study oligonucleotide 
microarray analysis showed that the greater difference 
in DEFB4A mRNA level in comparison to controls was 
in SCC (FC = 13.35), in KA this difference was low-
er (FC = 9.86) and the lowest was in BCC (FC = 7.86). 
Significant fact is that all these non-melanoma skin pa-
thologies showed up-regulation of this gene. Until now, 
there has been no study concerning DEFB4A mRNA 
expression in KA, SCC and BCC simultaneously.
In the present study, the level of defensin beta 2 
mRNA in KA, SCC and BCC was validated by the 
use of real-time QRT-PCR. Due to a marked differ-
ence between the analysed tumours, the expres-
sion of β-actin mRNA could not be used for normal-
isation of the results obtained. Thus, the number 
of mRNA copies was recalculated per microgram 
of total RNA. All of the tumours analysed showed 
higher expression of DEFB4A mRNA compared 
with the margins of the healthy tissues. Our results 
are in agreement with other published data. Gambi-
chler et al. demonstrated up-regulation of DEFB4A 
mRNA in BCC compared with healthy controls (8). 
In oral SCC, Yoshimoto et al. observed the expres-
sion of HBD-2 both in inflamed lesions with bacteri-
al infection and non-inflamed carcinomas using the 
in situ hybridization technique (41). Moreover, they 
demonstrated the expression of HBD-2 in normal 
oral epithelia only in areas adjacent to the SCCs. 
Shi et al. reported overexpression of HBD-2 in rat 
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oesophageal squamous cell carcinoma (SCC) and 
in oesophageal SCC tissues in patients (6). We 
compared the mRNA level of the DEFB4A gene 
between KA, SCC and BCC. The expression was 
significantly higher both in KA and SCC compared 
with BCC. Our results showed that the expression 
of DEFB4A mRNA is similar in KA and SCC. How-
ever, such similarity does not indicate the same 
outcome in these two tumours. Defensin beta 2 is 
one of the most important factors involved in the 
immunological reaction and keratinisation. In KA, 
induction of the immune response, which inhib-
its uncontrolled growth and limits the prolifera-
tion potential of KA cells, may lead to its regres-
sion (21). Furthermore, the regression of KA may 
be related to the cessation of the differentiation of 
the cells, which become keratinised and are not 
able to proliferate any more, and, therefore, die. 
The cessation of the tumour cells’ differentiation is 
then manifested by keratinisation. Yoshimoto et al. 
suggested that HBD-2 may lead to the death of 
normal keratinocytes adjacent to the SCCs, which 
might, in turn, indirectly assist in the multiplication 
of tumour cells (41). The molecular mechanism 
underlying KA transformation into SCC is still un-
clear. Probably, transformed cells (SCC) present in 
the KA tumour proliferate during the keratinisation 
of KA. Along with changes at mRNA level of genes 
coding proteins involved in intracellular signaliza-
tion of KA common for BCC and SCC, changes in 
DEFB4A expression suggest complex interactions 
at protein level of unknown results. Therefore, plan-
ning therapeutic approaches to KA based on stim-
ulation of the DEFB4A gene expression should be 
considered carefully.
The defensin beta 2 mRNA level may constitute 
a useful tool for the differentiation of BCC from KA and 
from SCC. KA and SCC cannot be differentiated on the 
basis of the DEFB4A mRNA level. To definitely confirm 
the usefulness of the expression of defensin beta 2 
in differentiation of KA from SCC and BCC, more de-
tailed studies of larger populations are needed.
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